The endocannabinoid system, with its complex actions in our immune system, nervous system, and all of the body’s organs, is literally a bridge between body and mind. By understanding this system we begin to see a mechanism that explains how states of consciousness can promote health or disease.
In a study published last fall, researchers found that fewer than 1 in 10 medical schools included medical marijuana in their curricula. Two-thirds of medical school deans reported that their graduates “were not at all prepared to prescribe medical marijuana,” and a quarter reported that their graduates “were not at all prepared to answer questions about medical marijuana.”
In fact, cannabis science is one of the fastest moving frontiers in pharmacology and has accelerated by the realisation that we’re all already marinated in cannabis-like molecules (endocannabinoids) and their receptors. Endocannabinoids help regulate many physiological processes: mood, memory, appetite, pain, immune function, metabolism and bone growth to name a few (there are even cannabinoid receptors in sperm).
By studying how weed affects us, researchers got a much better sense of how the body functions when not under the influence of tetrahydrocannabinol (THC), the main active ingredient in cannabis. Because, it turned out, the endocannabinoid system wasn't just lying dormant waiting for THC to enter the body. It's working all the time. And, as one paper put it, "the endocannabinoids are literally a bridge between body and mind."
Only recently have we gleaned scientific insight into several of the pharmacologically distinct cannabinoids and their effects at specific receptors within various animals and humans.
ECS is a unique system in multiple dimensions. To begin with, it is a retrograde system functioning post- to pre-synapse, allowing it to be a “master regulator” in the body.
An overwhelming body of convincing preclinical evidence indicates that cannabinoids produce antinociceptive effects in inflammatory and neuropathic rodent pain models. Cannabinoid receptor agonists, endocannabinoid-regulating enzyme inhibitors, and other pharmacological strategies to manipulate the endogenous cannabinoids system decrease the hyperalgesia and allodynia induced in diverse inflammatory and neuropathic pain states.
After several decades of research, scientists studying the effects of marijuana made several important discoveries. Not only did they identify the active ingredient in marijuana, they also discovered where and how it works in the brain—via a new system they called the endocannabinoid (EC) system. The EC system—named after the marijuana plant Cannabis sativa and its active ingredient delta-9-tetrahydrocannabinol (THC)—is a unique communications system in the brain and body that affects many important functions, including how a person feels, moves, and reacts.
First identified in the late 1980s, the so-called endocannabinoid system consists of CB1 receptors predominantly located in the nervous system, connective tissues, gonads, glands, and organs; and CB2 receptors, primarily found in the immune system and also present in the spleen, liver, heart, kidneys, bones, blood vessels, lymph cells, endocrine glands, and reproductive organs.
Study of the ECS was initially focused on attempts to understand (and demonize) an illegal drug, but new research has since flourished into a far more broad-based exploration into what is an astoundingly intricate and far-reaching system by which our bodies learn, feel, motivate, and keep themselves in balance.
The ECS is perhaps most notable for its role in regulating the limbic system, a part of the brain responsible for emotions, motivation, and our stress response. This system responds to our body’s own endogenous cannabinoids, anandamide and 2-AG, and to exogenous cannabinoids.
Canntelligence will transform consumers and healthcare practitioner’s understanding of the endocannabinoid system and science of the cannabis plant.